<annotated version="1.0">
  <meta>
    <transcriber>ug</transcriber>
    <date>2014-09-17</date>
    <place>New Journal of Science. Copyright ¬© 2014 J. M. Dixon. This 
    is an open access article distributed under the Creative Commons 
    Attribution License</place>
    <author><gender>m</gender><age>?</age><region>?</region></author>
  </meta>
  <text>
    <heading><w c7="JJ">Endocrine</w><w c7="NN1">Resistance</w><w c7="II">in</w><w c7="NN1">Breast</w><w c7="NN1">Cancer</w></heading>
    <heading><w c7="MC1">1</w><w c7=".">.</w><w c7="NN1">Introduction</w></heading>
    <p><w c7="RR">Approximately</w><w c7="MC">70</w><w c7="NNU">%</w><w c7="IO">of</w><w c7="NN1">breast</w><w c7="NN2">cancers</w><w c7="VBR">are</w><w c7="VVN">considered</w><w c7="NN1">estrogen</w><w c7="NN1">receptor</w><w c7="NN1">alpha</w><w c7="(">(</w><w c7="NP1">ERùõº</w><w c7=")">)</w><w c7="CC">and</w><w c7="/">/</w><w c7="CC">or</w><w c7="NN1">progesterone</w><w c7="NN1">receptor</w><w c7="(">(</w><w c7="NP1">PR</w><w c7=")">)</w><w c7="JJ">positive</w><w c7=",">,</w><w c7="CC">and</w><w c7="AT">the</w><w c7="NN1">hormone</w><w c7="NN1">estrogen</w><w c7="(">(</w><w c7="NN1">17ùõΩ-estradiol</w><w c7=",">,</w><w c7="NP1">E2</w><w c7=")">)</w><w c7="VVZ">represents</w><w c7="AT">the</w><w c7="JJ">primary</w><w c7="NN1">stimulant</w><w c7="II">in</w><w c7="AT">the</w><w c7="NN1">growth</w><w c7="CC">and</w><w c7="NN1">development</w><w c7="IO">of</w><w c7="DD2">these</w><w c7="NN2">tumours</w><w c7="[">[</w><w c7="MC1">1</w><w c7="]">]</w><w c7=".">.</w><w c7="RR">Thus</w><w c7="NN1">deprivation</w><w c7="IO">of</w><w c7="NN1">estrogen</w><w c7="NN1">signalling</w><w c7="II">through</w><w c7="JJ">endocrine-targeted</w><w c7="NN1">therapy</w><w c7="VHZ">has</w><w c7="VVN">become</w><w c7="AT">the</w><w c7="NN1">mainstay</w><w c7="IO">of</w><w c7="NN1">treatment</w><w c7="II">in</w><w c7="JJ">ERùõº-positive</w><w c7="NN1">disease</w><w c7=".">.</w><w c7="II">Despite</w><w c7="AT">the</w><w c7="NN2">benefits</w><w c7=",">,</w><w c7="JJ">endocrine</w><w c7="NN1">therapy</w><w c7="NN1">resistance</w><w c7="RR">eventually</w><w c7="VVZ">occurs</w><w c7="II">in</w><w c7="AT1">a</w><w c7="JJ">large</w><w c7="NN1">number</w><w c7="IO">of</w><w c7="NN2">patients</w><w c7="CC">and</w><w c7="VVZ">represents</w><w c7="AT1">a</w><w c7="JJ">significant</w><w c7="NN1">issue</w><w c7="IF">for</w><w c7="JJ">optimal</w><w c7="JJ">clinical</w><w c7="NN1">management</w><w c7="[">[</w><w c7="MC">2</w><w c7="]">]</w><w c7=".">.</w><w c7="II">In</w><w c7="JJ">recent</w><w c7="NNT2">years</w><w c7="AT1">a</w><w c7="JJ">large</w><w c7="NN1">body</w><w c7="IO">of</w><w c7="NN1">work</w><w c7="VHZ">has</w><w c7="VVN">focused</w><w c7="II">on</w><w c7="VVG">trying</w><w c7="TO">to</w><w c7="VVI">understand</w><w c7="AT">the</w><w c7="JJ">underlying</w><w c7="NN2">mechanisms</w><w c7="VVG">leading</w><w c7="II">to</w><w c7="NN1">resistance</w><w c7="CC">and</w><w c7="NN2">approaches</w><w c7="IF">for</w><w c7="APPGE">their</w><w c7="NN1">circumvention</w><w c7=",">,</w><w c7="II31">as</w><w c7="II32">well</w><w c7="II33">as</w><w c7="VVG">developing</w><w c7="NN2">methods</w><w c7="TO">to</w><w c7="VVI">predict</w><w c7="DDQ">which</w><w c7="NN2">patients</w><w c7="VBR">are</w><w c7="JJ">likely</w><w c7="TO">to</w><w c7="VVI">develop</w><w c7="NN1">resistance</w><w c7="CC">and</w><w c7="VBR">are</w><w c7="RR">therefore</w><w c7="II31">in</w><w c7="II32">need</w><w c7="II33">of</w><w c7="JJ">additional</w><w c7="CC">or</w><w c7="JJ">alternative</w><w c7="NN2">therapies</w><w c7=".">.</w><w c7="CS">While</w><w c7="JJ">numerous</w><w c7="NN2">mechanisms</w><w c7="VH0">have</w><w c7="VBN">been</w><w c7="VVN">proposed</w><w c7="II31">in</w><w c7="II32">addition</w><w c7="II33">to</w><w c7="DD2">those</w><w c7="VVN">discussed</w><w c7="II">in</w><w c7="DD1">this</w><w c7="NN1">review</w><w c7=",">,</w><w c7="AT1">a</w><w c7="JJ">major</w><w c7="NN1">lesson</w><w c7="II">from</w><w c7="AT">the</w><w c7="NN1">laboratory</w><w c7="VHZ">has</w><w c7="VBN">been</w><w c7="AT">the</w><w c7="NN1">realisation</w><w c7="CST">that</w><w c7="NN1">resistance</w><w c7="VBZ">is</w><w c7="RR">both</w><w c7="RR">highly</w><w c7="JJ">complex</w><w c7="CC">and</w><w c7="JJ">heterogeneous</w><w c7="CC">and</w><w c7="PPH1">it</w><w c7="VBZ">is</w><w c7="JJ">clear</w><w c7="CST">that</w><w c7="DAR">more</w><w c7="NN1">work</w><w c7="VBZ">is</w><w c7="VVN">needed</w><w c7="TO">to</w><w c7="VVI">identify</w><w c7="CC">and</w><w c7="VVI">improve</w><w c7="JJ">clinical</w><w c7="NN1">outcome</w><w c7="IO">of</w><w c7="NN2">patients</w><w c7="IW">with</w><w c7="JJ">ER-positive</w><w c7="NN1">breast</w><w c7="NN2">cancers</w><w c7=".">.</w></p>
    <heading><w c7="MC">2</w><w c7=".">.</w><w c7="NN1">Estrogen</w><w c7="NN1">Production</w></heading>
    <p><w c7="II">In</w><w c7="RR">both</w><w c7="JJ">pre-</w><w c7="CC">and</w><w c7="JJ">postmenopausal</w><w c7="NN1">woman</w><w c7="NN1">estrogen</w><w c7="NN1">production</w><w c7="VVZ">occurs</w><w c7="RR">locally</w><w c7="II">in</w><w c7="AT">the</w><w c7="JJ">normal</w><w c7="NN2">tissues</w><w c7="IO">of</w><w c7="JJ">subcutaneous</w><w c7="NN1">fat</w><w c7=",">,</w><w c7="AT">the</w><w c7="NN1">breast</w><w c7=",">,</w><w c7="NN1">muscle</w><w c7="NN1">tissue</w><w c7="CC">and</w><w c7="NN1">bone</w><w c7=",">,</w><w c7="CS">where</w><w c7="PPH1">it</w><w c7="VBZ">is</w><w c7="VVN">produced</w><w c7="II">by</w><w c7="AT">the</w><w c7="JJ">enzymatic</w><w c7="NN1">conversion</w><w c7="IO">of</w><w c7="NN2">androgens</w><w c7="(">(</w><w c7="NN1">androstenedione</w><w c7="CC">and</w><w c7="NN1">testosterone</w><w c7=")">)</w><w c7="II">by</w><w c7="NN1">aromatase</w><w c7="[">[</w><w c7="MC1">1</w><w c7=",">,</w><w c7="MCMC">3‚Äì8</w><w c7="]">]</w><w c7="(">(</w><w c7="NP1">Figure</w><w c7="MC1">1</w><w c7=")">)</w><w c7=".">.</w><w c7="II">Within</w><w c7="NN1">breast</w><w c7="NN1">cancer</w><w c7="NN1">tissue</w><w c7=",">,</w><w c7="NN1">expression</w><w c7="IO">of</w><w c7="NN1">aromatase</w><w c7="VVZ">occurs</w><w c7="RR">mainly</w><w c7="II">in</w><w c7="NN2">fibroblasts</w><w c7="[">[</w><w c7="MC">9</w><w c7="]">]</w><w c7=".">.</w><w c7="JJ">Residual</w><w c7="NN2">levels</w><w c7="IO">of</w><w c7="NN1">estrogen</w><w c7="VBR">are</w><w c7="RR">also</w><w c7="RR">commonly</w><w c7="VVN">found</w><w c7="VVG">circulating</w><w c7="II">in</w><w c7="AT">the</w><w c7="NN1">blood</w><w c7="CC">and</w><w c7="VBR">are</w><w c7="RG">around</w><w c7="JJ">20-fold</w><w c7="JJR">higher</w><w c7="II">in</w><w c7="JJ">postmenopausal</w><w c7="NN2">women</w><w c7="VVN">compared</w><w c7="IW">with</w><w c7="JJ">premenopausal</w><w c7="NN2">women</w><w c7=",">,</w><w c7="II">despite</w><w c7="AT">the</w><w c7="NN1">loss</w><w c7="IO">of</w><w c7="JJ">ovarian</w><w c7="NN1">estrogen</w><w c7="NN1">production</w><w c7="[">[</w><w c7="MC">4</w><w c7=",">,</w><w c7="MC">5</w><w c7=",">,</w><w c7="MC">10</w><w c7="]">]</w><w c7=".">.</w><w c7="II">In</w><w c7="JJ">postmenopausal</w><w c7="NN2">women</w><w c7="EX">there</w><w c7="VBZ">is</w><w c7="AT1">a</w><w c7="JJ">noticeable</w><w c7="NN1">correlation</w><w c7="II">between</w><w c7="NN1">risk</w><w c7="IO">of</w><w c7="NN1">breast</w><w c7="NN1">cancer</w><w c7="CC">and</w><w c7="NN2">levels</w><w c7="IO">of</w><w c7="VVG">circulating</w><w c7="NN1">estrogen</w><w c7="II">in</w><w c7="AT">the</w><w c7="NN1">blood</w><w c7="NN1">plasma</w><w c7="[">[</w><w c7="MC">11</w><w c7="]">]</w><w c7=".">.</w><w c7="NN1">Aromatase</w><w c7="NN1">transcription</w><w c7="CC">and</w><w c7="NN1">protein</w><w c7="NN2">levels</w><w c7="VH0">have</w><w c7="VBN">been</w><w c7="VVN">shown</w><w c7="TO">to</w><w c7="VVI">differ</w><w c7="II">between</w><w c7="AT">the</w><w c7="NN2">quadrants</w><w c7="IO">of</w><w c7="AT">the</w><w c7="NN1">breast</w><w c7="II">in</w><w c7="NN2">women</w><w c7="IW">with</w><w c7="NN1">breast</w><w c7="NN1">cancer</w><w c7=",">,</w><w c7="VBG">being</w><w c7="RR">considerably</w><w c7="JJ">increased</w><w c7="II">in</w><w c7="AT">the</w><w c7="NN1">quadrant</w><w c7="VVG">containing</w><w c7="AT">the</w><w c7="NN1">tumour</w><w c7="[">[</w><w c7="MC">12</w><w c7=",">,</w><w c7="MC">13</w><w c7="]">]</w><w c7=".">.</w><w c7="NN1">Evidence</w><w c7="VVZ">suggests</w><w c7="CST">that</w><w c7="DD1">this</w><w c7="VBZ">is</w><w c7="RR">primarily</w><w c7="II21">due</w><w c7="II22">to</w><w c7="NN1">tumour</w><w c7="JJ">cell-released</w><w c7="NN2">factors</w><w c7="II21">such</w><w c7="II22">as</w><w c7="NN2">prostaglandins</w><w c7="CC">and</w><w c7="JJ">inflammatory</w><w c7="NN1">cell</w><w c7="JJ">released</w><w c7="NN2">cytokines</w><w c7="II21">such</w><w c7="II22">as</w><w c7="NP1">IL6</w><w c7=",">,</w><w c7="NP1">IL11</w><w c7="CC">and</w><w c7="NP1">TNFùõº</w><w c7=",">,</w><w c7="DDQ">which</w><w c7="VV0">enhance</w><w c7="AT">the</w><w c7="NN1">activity</w><w c7="IO">of</w><w c7="NN1">aromatase</w><w c7="II">in</w><w c7="NN2">fibroblasts</w><w c7="II">through</w><w c7="JJ">intracellular</w><w c7="NP1">cAMP</w><w c7="NN1">signalling</w><w c7="CC">and</w><w c7="NN1">regulation</w><w c7="IO">of</w><w c7="AT">the</w><w c7="NN1">aromatase</w><w c7="NN1">gene</w><w c7="(">(</w><w c7="NP1">CYP19</w><w c7=")">)</w><w c7="II">via</w><w c7="AT1">an</w><w c7="JJ">alternative</w><w c7="JJ">non-standard</w><w c7="NN1">promoter</w><w c7="[">[</w><w c7="MC1">1</w><w c7=",">,</w><w c7="MC">14</w><w c7=",">,</w><w c7="MC">15</w><w c7="]">]</w><w c7=".">.</w></p>
    <heading><w c7="MC">3</w><w c7=".">.</w><w c7="NN1">Estrogen</w><w c7="NN1">Signalling</w></heading>
    <p><w c7="II">In</w><w c7="JJ">hormone-dependent</w><w c7="NN2">cancers</w><w c7=",">,</w><w c7="NN1">estrogen</w><w c7="VVN">taken</w><w c7="RP">up</w><w c7="II">from</w><w c7="AT">the</w><w c7="NN1">blood</w><w c7="NN1">plasma</w><w c7="CC">or</w><w c7="II">from</w><w c7="JJ">local</w><w c7="NN1">production</w><w c7="VVZ">diffuses</w><w c7="II">into</w><w c7="AT">the</w><w c7="NN1">cancer</w><w c7="NN1">cell</w><w c7="CC">and</w><w c7="VVZ">binds</w><w c7="NP1">ER</w><w c7=",">,</w><w c7="RR">thus</w><w c7="VVG">causing</w><w c7="AT">the</w><w c7="NN1">dissociation</w><w c7="IO">of</w></p>
    <p><object type="graphic" /></p>
    <p><w c7="NP1">Figure</w><w c7="MC1">1</w><w c7=":">:</w><w c7="NN1">Diagram</w><w c7="VVG">showing</w><w c7="JJ">local</w><w c7="NN1">estrogen</w><w c7="NN1">production</w><w c7="II">via</w><w c7="AT">the</w><w c7="JJ">enzymatic</w><w c7="NN1">conversion</w><w c7="IO">of</w><w c7="NN2">androgens</w><w c7="II">to</w><w c7="NN1">estrogen</w><w c7="II">by</w><w c7="NN1">aromatase</w><w c7="CC">and</w><w c7="NN1">estrogen</w><w c7="NN1">receptor</w><w c7="NN1">signalling</w><w c7="II">in</w><w c7="NN1">breast</w><w c7="NN1">cancer</w><w c7=".">.</w><w c7="NP1">Estrogen</w><w c7="(">(</w><w c7="NP1">E</w><w c7=")">)</w><w c7=",">,</w><w c7="NN1">estrogen</w><w c7="NN1">receptor</w><w c7="NN1">alpha</w><w c7="(">(</w><w c7="NP1">ER</w><w c7=")">)</w><w c7=",">,</w><w c7="NN1">estrogen</w><w c7="NN1">response</w><w c7="NN1">element</w><w c7="(">(</w><w c7="NP1">ERE</w><w c7=")">)</w><w c7="CC">and</w><w c7="NN1">heat-shock</w><w c7="NN2">proteins</w><w c7="(">(</w><w c7="NP1">HSP</w><w c7=")">)</w><w c7=".">.</w><w c7="AT">The</w><w c7="NN2">targets</w><w c7="IO">of</w><w c7="RR">commonly</w><w c7="JJ">used</w><w c7="JJ">endocrine</w><w c7="NN2">therapies</w><w c7="II">in</w><w c7="AT">the</w><w c7="NN1">pathway</w><w c7="VBR">are</w><w c7="VVN">shown</w><w c7=":">:</w><w c7="NN1">aromatase</w><w c7="NN2">inhibitors</w><w c7="(">(</w><w c7="NP1">AI</w><w c7=")">)</w><w c7=",">,</w><w c7="NN1">tamoxifen</w><w c7="(">(</w><w c7="NP1">T</w><w c7=")">)</w><w c7="CC">and</w><w c7="NN1">fulvestrant</w><w c7="(">(</w><w c7="NP1">F</w><w c7=")">)</w><w c7=".">.</w></p>
    <p><w c7="NN1">heat</w><w c7="NN1">shock</w><w c7="NN2">proteins</w><w c7="II">from</w><w c7="AT">the</w><w c7="NP1">ER</w><w c7="NN1">molecule</w><w c7=".">.</w><w c7="AT">The</w><w c7="JJ">ligand-bound</w><w c7="NN1">molecule</w><w c7="VVZ">dimerises</w><w c7=",">,</w><w c7="VVZ">associates</w><w c7="IW">with</w><w c7="JJ">other</w><w c7="NN1">coactivator</w><w c7="CC">or</w><w c7="NN1">corepressor</w><w c7="NN2">proteins</w><w c7="CC">and</w><w c7="RR">subsequently</w><w c7="VVZ">binds</w><w c7="II">to</w><w c7="JJ">conserved</w><w c7="NN1">estrogen</w><w c7="NN1">response</w><w c7="NN1">element</w><w c7="(">(</w><w c7="NP1">ERE</w><w c7=")">)</w><w c7="NN2">sequences</w><w c7="II">within</w><w c7="AT">the</w><w c7="NN1">promoter</w><w c7="NN2">regions</w><w c7="IO">of</w><w c7="NN2">genes</w><w c7="II">over</w><w c7="DDQ">which</w><w c7="PPH1">it</w><w c7="VVZ">exerts</w><w c7="JJ">transcriptional</w><w c7="NN1">control</w><w c7="[">[</w><w c7="MC1">1</w><w c7=",">,</w><w c7="MC">16</w><w c7="]">]</w><w c7="(">(</w><w c7="NP1">Figure</w><w c7="MC1">1</w><w c7=")">)</w><w c7=".">.</w><w c7="NP1">ER</w><w c7="VBZ">is</w><w c7="AT1">a</w><w c7="JJ">nuclear</w><w c7="NN1">receptor</w><w c7="VVN">encoded</w><w c7="II">by</w><w c7="AT">the</w><w c7="NP1">ESR1</w><w c7="NN1">gene</w><w c7=";">;</w><w c7="PPH1">it</w><w c7="VVZ">comprises</w><w c7="MC">two</w><w c7="JJ">distinct</w><w c7="NN1">transactivation</w><w c7="NN2">domains</w><w c7=":">:</w><w c7="NN1">activation</w><w c7="NN1">function</w><w c7="(">(</w><w c7="NP1">AF</w><w c7=")">)</w><w c7="MC">-1</w><w c7="II">in</w><w c7="AT">the</w><w c7="NN1">amino-terminal</w><w c7="NN1">region</w><w c7="CC">and</w><w c7="NP1">AF2</w><w c7="II">in</w><w c7="AT">the</w><w c7="NN1">carboxy-terminal</w><w c7="NN1">region</w><w c7="[">[</w><w c7="MCMC">17‚Äì19</w><w c7="]">]</w><w c7=".">.</w><w c7="NP1">AF1</w><w c7="VBZ">is</w><w c7="VVN">regulated</w><w c7="II">by</w><w c7="NN1">growth</w><w c7="NN2">factors</w><w c7="VVG">acting</w><w c7="II">through</w><w c7="AT">the</w><w c7="NP1">MAPK</w><w c7="NN1">pathway</w><w c7="CS">whereas</w><w c7="NP1">AF2</w><w c7=",">,</w><w c7="VVN">located</w><w c7="II">in</w><w c7="AT">the</w><w c7="NN1">ligand</w><w c7="JJ">binding</w><w c7="NN1">region</w><w c7="IO">of</w><w c7="NP1">ER</w><w c7="VBZ">is</w><w c7="VVN">activated</w><w c7="II">by</w><w c7="NN1">estrogen</w><w c7="[">[</w><w c7="MC">17</w><w c7=",">,</w><w c7="MC">20</w><w c7="]">]</w><w c7=".">.</w><w c7="JJ">Full</w><w c7="NN1">agonist</w><w c7="NN1">activity</w><w c7="VVZ">requires</w><w c7="RR">both</w><w c7="NP1">AF1</w><w c7="CC">and</w><w c7="NP1">AF2</w><w c7="TO">to</w><w c7="VBI">be</w><w c7="JJ">active</w><w c7="[">[</w><w c7="MC">21</w><w c7="]">]</w><w c7=".">.</w><w c7="NN2">Studies</w><w c7="VH0">have</w><w c7="VVN">shown</w><w c7="CST">that</w><w c7="NP1">ERE</w><w c7="JJ">bound</w><w c7="NP1">ER</w><w c7="VBZ">is</w><w c7="VVN">ubiquitinated</w><w c7="CC">and</w><w c7="VVN">targeted</w><w c7="IF">for</w><w c7="JJ">proteosomal</w><w c7="NN1">degradation</w><w c7=",">,</w><w c7="VVG">suggesting</w><w c7="CST">that</w><w c7="DD1">each</w><w c7="NP1">ER</w><w c7="NN1">molecule</w><w c7="VBZ">is</w><w c7="VVN">destined</w><w c7="IF">for</w><w c7="RR">only</w><w c7="MC1">one</w><w c7="NN1">cycle</w><w c7="IO">of</w><w c7="NN1">estrogen</w><w c7="NN1">signalling</w><w c7="[">[</w><w c7="MC">22</w><w c7="]">]</w><w c7=".">.</w><w c7="NP2">EREs</w><w c7="VBDR">were</w><w c7="MD">first</w><w c7="VVN">discovered</w><w c7="VVG">flanking</w><w c7="AT">the</w><w c7="NN2">regions</w><w c7="IO">of</w><w c7="JJ">estrogen-regulated</w><w c7="NN1">vitellogennin</w><w c7="NN2">genes</w><w c7="II">in</w><italics><w c7="FW21">Xenopus</w><w c7="FW22">laevis</w></italics><w c7="CC">and</w><w c7="VH0">have</w><w c7="RR">since</w><w c7="VBN">been</w><w c7="VVN">found</w><w c7="II">in</w><w c7="AT">the</w><w c7="NN1">promoter</w><w c7="NN2">regions</w><w c7="IO">of</w><w c7="DA2">several</w><w c7="NNO">hundred</w><w c7="JJ">human</w><w c7="NN2">genes</w><w c7=",">,</w><w c7="IW">with</w><w c7="AT1">a</w><w c7="JJ">minimum</w><w c7="NN1">consensus</w><w c7="NN1">sequence</w><w c7="VVG">consisting</w><w c7="IO">of</w><w c7="AT1">a</w><w c7="MC">13</w><w c7="NN1">base-pair</w><w c7="JJ">palindromic</w><w c7="JJ">inverted</w><w c7="NN1">repeat</w><w c7=":">:</w><w c7="FO">5'-GGTCANNNTGACC-3'</w><w c7="(">(</w><w c7="NP1">N</w><w c7=":">:</w><w c7="DD">any</w><w c7="NN1">nucleotide</w><w c7=")">)</w><w c7="[">[</w><w c7="MCMC">23‚Äì25</w><w c7="]">]</w><w c7=".">.</w><w c7="DD">Some</w><w c7="NP2">EREs</w><w c7="VH0">have</w><w c7="VBN">been</w><w c7="VVN">identified</w><w c7="DDQ">which</w><w c7="VH0">have</w><w c7="JJ">imperfect</w><w c7="JJ">palindromic</w><w c7="NN2">sequences</w><w c7=",">,</w><w c7="VVG">differing</w><w c7="II">from</w><w c7="AT">the</w><w c7="NN1">consensus</w><w c7="NN1">sequence</w><w c7="II">by</w><w c7="MC1">one</w><w c7="CC">or</w><w c7="DAR">more</w><w c7="NN2">nucleotides</w><w c7="CC">and</w><w c7="VBR">are</w><w c7="RR">often</w><w c7="RGR">less</w><w c7="JJ">responsive</w><w c7="TO">to</w><w c7="JJ">ligand-bound</w><w c7="NP1">ER</w><w c7="CSN">than</w><w c7="NN1">consensus</w><w c7="NN1">sequence</w><w c7="NP2">EREs</w><w c7="[">[</w><w c7="MC">26</w><w c7="]">]</w><w c7=".">.</w><w c7="AT">The</w><w c7="NN1">association</w><w c7="IO">of</w><w c7="JJ">ligand-bound</w><w c7="NP1">ER</w><w c7="IW">with</w><w c7="NP2">EREs</w><w c7="VBZ">is</w><w c7="VVN">thought</w><w c7="TO">to</w><w c7="VBI">be</w><w c7="VVN">achieved</w><w c7="II">via</w><w c7="DD1">either</w><w c7="IO">of</w><w c7="MC">two</w><w c7="NN2">mechanisms</w><w c7=":">:</w><w c7="(">(</w><w c7="MC1">i</w><w c7=")">)</w><w c7="&quot;">"</w><w c7="JJ">direct</w><w c7="NN1">binding</w><w c7="&quot;">"</w><w c7="II">in</w><w c7="DDQ">which</w><w c7="AT">the</w><w c7="NN1">molecule</w><w c7="VVZ">binds</w><w c7="II">to</w><w c7="AT">the</w><w c7="NP2">EREs</w><w c7="CC">and</w><w c7="VVZ">associates</w><w c7="RR">directly</w><w c7="IW">with</w><w c7="NN1">coactivator</w><w c7="/">/</w><w c7="NN1">corepressor</w><w c7="NN2">molecules</w><w c7="CC">and</w><w c7="AT">the</w><w c7="NP1">RNA</w><w c7="NN1">polymerase</w><w c7="MC">II</w><w c7="NN1">transcription</w><w c7="NN1">initiation</w><w c7="NN1">complex</w><w c7=",">,</w><w c7="CC">or</w><w c7="(">(</w><w c7="MC">ii</w><w c7=")">)</w><w c7="&quot;">"</w><w c7="NN1">tethering</w><w c7="&quot;">"</w><w c7="RRQ">whereby</w><w c7="AT">the</w><w c7="JJ">ligand-bound</w><w c7="NP1">ER</w><w c7="VDZ">does</w><w c7="XX">not</w><w c7="VVI">bind</w><w c7="NN1">DNA</w><w c7="CCB">but</w><w c7="RR">rather</w><w c7="VVZ">interacts</w><w c7="IW">with</w><w c7="DD1">another</w><w c7="NN1">DNA</w><w c7="JJ">bound</w><w c7="NN1">transcription</w><w c7="NN1">factor</w><w c7="RR">either</w><w c7="VVG">stabilising</w><w c7="DD1">that</w><w c7="NN1">factor</w><w c7=",">,</w><w c7="CC">or</w><w c7="VVG">recruiting</w><w c7="JJ">additional</w><w c7="NN2">cofactors</w><w c7="II">to</w><w c7="AT">the</w><w c7="NN1">complex</w><w c7="[">[</w><w c7="MC">27</w><w c7=",">,</w><w c7="MC">28</w><w c7="]">]</w><w c7=".">.</w><w c7="AT">The</w><w c7="DA">latter</w><w c7="VBZ">is</w><w c7="VVN">thought</w><w c7="TO">to</w><w c7="VBI">be</w><w c7="AT">the</w><w c7="NN1">mechanism</w><w c7="II">by</w><w c7="DDQ">which</w><w c7="JJ">ligand-bound</w><w c7="NP1">ER</w><w c7="VVZ">associates</w><w c7="IW">with</w><w c7="NN1">transcription</w><w c7="NN1">factor</w><w c7="NP1">SP1</w><w c7="[">[</w><w c7="MC">27</w><w c7="]">]</w><w c7=".">.</w><w c7="II">Via</w><w c7="DD2">these</w><w c7="JJ">transcriptional</w><w c7="NN2">associations</w><w c7="NN1">estrogen</w><w c7="VM">can</w><w c7="VVI">induce</w><w c7="NN1">proliferation</w><w c7="IO">of</w><w c7="NN1">cancer</w><w c7="NN2">cells</w><w c7="DDQ">which</w><w c7="JJ">overexpress</w><w c7="NP1">ER</w><w c7=".">.</w><w c7="PPH1">It</w><w c7="VM">should</w><w c7="VBI">be</w><w c7="VVN">noted</w><w c7="CST">that</w><w c7="JJ">non-ligand-bound</w><w c7="NP1">ER</w><w c7="NN2">complexes</w><w c7="VM">can</w><w c7="RR">also</w><w c7="VVI">bind</w><w c7="II">to</w><w c7="NP2">EREs</w><w c7=",">,</w><w c7="IW">without</w><w c7="AT">the</w><w c7="NN1">ability</w><w c7="TO">to</w><w c7="VVI">regulate</w><w c7="NN1">gene</w><w c7="NN1">expression</w><w c7="PPH1">it</w><w c7="VBDZ">was</w><w c7="VVN">thought</w><w c7="[">[</w><w c7="MC">17</w><w c7=",">,</w><w c7="MCMC">29‚Äì31</w><w c7="]">]</w><w c7="RR">however</w><w c7=",">,</w><w c7="JJ">recent</w><w c7="NN1">chromatin</w><w c7="NN1">immunoprecipitation</w><w c7="NN1">sequencing</w><w c7="NN">data</w><w c7="(">(</w><w c7="NP1">ChIP-seq</w><w c7=")">)</w><w c7="II">from</w><w c7="NP1">MCF7</w><w c7="NN1">breast</w><w c7="NN1">cancer</w><w c7="NN1">cell</w><w c7="NN2">lines</w><w c7="VVZ">suggests</w><w c7="CST">that</w><w c7="JJ">endogenous</w><w c7="NP1">ERùõº</w><w c7="VM">can</w><w c7="VVI">bind</w><w c7="NN1">DNA</w><w c7="II">in</w><w c7="AT">the</w><w c7="NN1">absence</w><w c7="IO">of</w><w c7="AT">the</w><w c7="NN1">ligand</w><w c7="CC">and</w><w c7="CST">that</w><w c7="NN2">transcripts</w><w c7="VBR">are</w><w c7="VVN">produced</w><w c7="II">at</w><w c7="DD2">those</w><w c7="NN2">sites</w><w c7="[">[</w><w c7="MC">32</w><w c7="]">]</w><w c7=".">.</w></p>
    <p><w c7="CS">Although</w><w c7="AT">the</w><w c7="JJ">exact</w><w c7="NN2">mechanisms</w><w c7="II">by</w><w c7="DDQ">which</w><w c7="NN1">estrogen</w><w c7="VVZ">drives</w><w c7="NN1">proliferation</w><w c7="VBR">are</w><w c7="RR">yet</w><w c7="TO">to</w><w c7="VBI">be</w><w c7="RR">fully</w><w c7="VVN">elucidated</w><w c7=",">,</w><w c7="AT1">a</w><w c7="NN1">number</w><w c7="IO">of</w><w c7="JJ">potential</w><w c7="NN2">models</w><w c7="VH0">have</w><w c7="VBN">been</w><w c7="VVN">proposed</w><w c7="[">[</w><w c7="MC">33</w><w c7="]">]</w><w c7=".">.</w><w c7="II">In</w><w c7="JJ">normal</w><w c7="JJ">human</w><w c7="NN1">breast</w><w c7="NN1">tissue</w><w c7=",">,</w><w c7="NN2">cells</w><w c7="DDQ">which</w><w c7="VD0">do</w><w c7="XX">not</w><w c7="VVI">express</w><w c7="NP1">ER</w><w c7="VV0">proliferate</w><w c7="II">via</w><w c7="JJ">paracrine</w><w c7="NN1">signalling</w><w c7=",">,</w><w c7="CS">whereas</w><w c7="II">in</w><w c7="NN2">tumours</w><w c7="AT1">an</w><w c7="JJ">autocrine</w><w c7="NN1">action</w><w c7="VVZ">occurs</w><w c7="II">in</w><w c7="DDQ">which</w><w c7="JJ">ER-positive</w><w c7="NN2">cells</w><w c7="VV0">proliferate</w><w c7="[">[</w><w c7="MC">34</w><w c7="]">]</w><w c7=".">.</w><w c7="PPH1">It</w><w c7="VHZ">has</w><w c7="VBN">been</w><w c7="VVN">reported</w><w c7="CST">that</w><w c7="NN1">estrogen</w><w c7="VVZ">promotes</w><w c7="NN1">transition</w><w c7="II">through</w><w c7="AT">the</w><w c7="NP1">G1/S</w><w c7="NN1">phase</w><w c7="IO">of</w><w c7="NN1">cell</w><w c7="NN1">cycle</w><w c7="II">via</w><w c7="AT1">a</w><w c7="NN1">number</w><w c7="IO">of</w><w c7="NN2">pathways</w><w c7="VVG">involving</w><w c7="AT">the</w><w c7="NN1">induction</w><w c7="IO">of</w><w c7="NP1">cyclin-D1</w><w c7="NN1">expression</w><w c7="II">by</w><w c7="JJ">ligand-bound</w><w c7="NP1">ER</w><w c7=",">,</w><w c7="VVN">mediated</w><w c7="II">by</w><w c7="MC1">one</w><w c7="CC">or</w><w c7="DAR">more</w><w c7="NN1">transcription</w><w c7="NN2">factors</w><w c7="II">including</w><w c7=":">:</w><w c7="NP1">c-Jun</w><w c7=",">,</w><w c7="NP1">c-Fos</w><w c7=",">,</w><w c7="CC">and</w><w c7="NP1">ATF-2</w><w c7="II">at</w><w c7="AT">the</w><w c7="NP1">AP1</w><w c7="NN1">promoter</w><w c7="NN1">site</w><w c7=",">,</w><w c7="CC">or</w><w c7="II">via</w><w c7="AT1">an</w><w c7="NP1">SP1</w><w c7="NN1">transcription</w><w c7="NN1">factor</w><w c7="JJ">dependent</w><w c7="NN1">pathway</w><w c7="[">[</w><w c7="MCMC">35‚Äì41</w><w c7="]">]</w><w c7=".">.</w><w c7="RR">Furthermore</w><w c7=",">,</w><w c7="JJ">ligand-bound</w><w c7="NP1">ER</w><w c7="VHZ">has</w><w c7="RR">also</w><w c7="VBN">been</w><w c7="VVN">shown</w><w c7="TO">to</w><w c7="VVI">bind</w><w c7="NP1">cyclin-D1</w><w c7="CC">and</w><w c7=",">,</w><w c7="II">as</w><w c7="AT1">a</w><w c7="JJ">complex</w><w c7=",">,</w><w c7="VVI">regulate</w><w c7="AT">the</w><w c7="NN1">expression</w><w c7="IO">of</w><w c7="DD1">that</w><w c7="NN1">gene</w><w c7="CC">and</w><w c7="JJ">other</w><w c7="JJ">downstream</w><w c7="NN2">genes</w><w c7="[">[</w><w c7="MC">39</w><w c7=",">,</w><w c7="MC">42</w><w c7="]">]</w><w c7=".">.</w><w c7="NP1">Cyclin-D1</w><w c7="RR">subsequently</w><w c7="VVZ">binds</w><w c7="CC">and</w><w c7="VVZ">activates</w><w c7="NP1">CDK4</w><w c7="CC">and</w><w c7="NP1">CDK6</w><w c7=",">,</w><w c7="DDQ">which</w><w c7="VV0">regulate</w><w c7="NP1">G1/S</w><w c7="NN1">phase</w><w c7="NN1">transition</w><w c7="II">through</w><w c7="AT">the</w><w c7="NN1">phosphorylation</w><w c7="IO">of</w><w c7="NP1">RB1</w><w c7=".">.</w><w c7="AT">The</w><w c7="DA">latter</w><w c7="VM">can</w><w c7="RR21">no</w><w c7="RR22">longer</w><w c7="VVI">inhibit</w><w c7="NP1">E2F/DP1</w><w c7="NN2">complexes</w><w c7=",">,</w><w c7="RR">thus</w><w c7="VVG">allowing</w><w c7="PPHO2">them</w><w c7="TO">to</w><w c7="VVI">activate</w><w c7="AT">the</w><w c7="NN1">transcription</w><w c7="IO">of</w><w c7="NN1">S-phase</w><w c7="NN1">entry</w><w c7="NN2">genes</w><w c7="II21">such</w><w c7="II22">as</w><w c7="DD2">those</w><w c7="VVG">encoding</w><w c7="NP1">cyclin-E1</w><w c7="CC">and</w><w c7="NP1">cyclin-A1</w><w c7="[">[</w><w c7="MC">35</w><w c7=",">,</w><w c7="MC">36</w><w c7=",">,</w><w c7="MC">43</w><w c7=",">,</w><w c7="MC">44</w><w c7="]">]</w><w c7=".">.</w><w c7="JJ">Other</w><w c7="NN2">studies</w><w c7="VV0">suggest</w><w c7="CST">that</w><w c7="JJ">ligand-bound</w><w c7="NP1">ER</w><w c7="VM">may</w><w c7="VVI">promote</w><w c7="NP1">G1/S</w><w c7="NN1">phase</w><w c7="NN1">transition</w><w c7="II">by</w><w c7="NN1">induction</w><w c7="IO">of</w><w c7="NP1">c-MYC</w><w c7="DDQ">which</w><w c7="VVZ">leads</w><w c7="II">to</w><w c7="NN1">activation</w><w c7="IO">of</w><w c7="NP1">CDC25A</w><w c7="CC">and</w><w c7="NP1">CDK4</w><w c7="NN1">gene</w><w c7="NN1">transcription</w><w c7="[">[</w><w c7="MCMC">45‚Äì47</w><w c7="]">]</w><w c7=".">.</w><w c7="JJ">Active</w><w c7="NP1">CDC25A</w><w c7="VVZ">dephosphorylates</w><w c7="NP1">CDK2</w><w c7="VVG">leading</w><w c7="II">to</w><w c7="AT">the</w><w c7="NN1">inhibition</w><w c7="IO">of</w><w c7="NP1">RB1</w><w c7="CC">and</w><w c7="NP1">p130</w><w c7="CC">and</w><w c7="JJ">transcriptional</w><w c7="NN1">activation</w><w c7="IO">of</w><w c7="NP1">E2F/DP1</w><w c7="NN2">complexes</w><w c7="DDQ">which</w><w c7="II">in</w><w c7="NN1">turn</w><w c7="VVZ">upregulates</w><w c7="NN1">S-phase</w><w c7="NN1">entry</w><w c7="NN2">genes</w><w c7="[">[</w><w c7="MC">36</w><w c7=",">,</w><w c7="MC">48</w><w c7=",">,</w><w c7="MC">49</w><w c7="]">]</w><w c7=".">.</w><w c7="RR">Alternatively</w><w c7=",">,</w><w c7="PPH1">it</w><w c7="VHZ">has</w><w c7="VBN">been</w><w c7="VVN">proposed</w><w c7="CST">that</w><w c7="NP1">ER</w><w c7="VM">could</w><w c7="VVI">activate</w><w c7="NP1">G1/S</w><w c7="NN1">phase</w><w c7="NN1">transition</w><w c7="II">via</w><w c7="NN1">redistribution</w><w c7="CC">and</w><w c7="NN1">downregulation</w><w c7="IO">of</w><w c7="NP1">p21</w><w c7="CC">and</w><w c7="NP1">P27KIP1</w><w c7="RR">thus</w><w c7="VVG">removing</w><w c7="APPGE">their</w><w c7="JJ">inhibitory</w><w c7="NN1">control</w><w c7="II">over</w><w c7="JJ">key</w><w c7="NN1">cell</w><w c7="NN1">cycle</w><w c7="NN1">progression</w><w c7="NN2">proteins</w><w c7="II21">such</w><w c7="II22">as</w><w c7="NP1">CDK2</w><w c7="[">[</w><w c7="MC">49</w><w c7=",">,</w><w c7="MC">50</w><w c7="]">]</w><w c7=".">.</w><w c7="PPH1">It</w><w c7="VBZ">is</w><w c7="VVN">thought</w><w c7="DD1">this</w><w c7="VM">might</w><w c7="VBI">be</w><w c7="VVN">achieved</w><w c7="II">by</w><w c7="NN1">ubiquitin</w><w c7="NN1">targeting</w><w c7="IF">for</w><w c7="JJ">proteosomal</w><w c7="NN1">degradation</w><w c7="CC">or</w><w c7="II">by</w><w c7="JJ">nuclear</w><w c7="NN1">export</w><w c7="II">via</w><w c7="JJ">membrane-bound</w><w c7="NP1">ER</w><w c7="VVN">associated</w><w c7="IW">with</w><w c7="NP1">ERK2</w><w c7="CC">and</w><w c7="NP1">CRM1</w><w c7="[">[</w><w c7="MC">51</w><w c7=",">,</w><w c7="MC">52</w><w c7="]">]</w><w c7=".">.</w></p>
    <heading><w c7="MC">4</w><w c7=".">.</w><w c7="JJ">Endocrine</w><w c7="NN1">Therapy</w></heading>
    <p><w c7="II">In</w><w c7="MC">1896</w><w c7="NP1">George</w><w c7="NP1">Beatson</w><w c7=",">,</w><w c7="AT1">a</w><w c7="NP1">Glasgow</w><w c7="NN1">surgeon</w><w c7=",">,</w><w c7="VVD">showed</w><w c7="CST">that</w><w c7="NN2">patients</w><w c7="IW">with</w><w c7="JJ">advanced</w><w c7="NN1">breast</w><w c7="NN1">cancer</w><w c7="VHD">had</w><w c7="NN1">regression</w><w c7="IO">of</w><w c7="JJ">metastatic</w><w c7="NN1">disease</w><w c7="VVG">following</w><w c7="NN1">oophorectomy</w><w c7=",">,</w><w c7="VVG">providing</w><w c7="AT">the</w><w c7="MD">first</w><w c7="JJ">contemporaneous</w><w c7="JJ">published</w><w c7="NN1">evidence</w><w c7="IO">of</w><w c7="AT1">a</w><w c7="NN1">link</w><w c7="II">between</w><w c7="NN2">hormones</w><w c7="CC">and</w><w c7="NN1">breast</w><w c7="NN1">cancer</w><w c7=".">.</w><w c7="II">By</w><w c7="MC">1937</w><w c7="NP1">Dodds</w><w c7="CC">and</w><w c7="NP1">Robertson</w><w c7="VHD">had</w><w c7="VVN">synthesised</w><w c7="NN1">diethylstilboestrol</w><w c7="CC">and</w><w c7="APPGE">its</w><w c7="JJ">anti-tumour</w><w c7="NN1">activity</w><w c7="VBDZ">was</w><w c7="VVN">demonstrated</w><w c7="CS">although</w><w c7="APPGE">its</w><w c7="NN1">use</w><w c7="VBDZ">was</w><w c7="VVN">limited</w><w c7="II">by</w><w c7="JJ">severe</w><w c7="NN1">side</w><w c7="NN2">effects</w><w c7="(">(</w><w c7="NP1">Figure</w><w c7="MC">2</w><w c7=")">)</w><w c7="[">[</w><w c7="MC">53</w><w c7="]">]</w><w c7=".">.</w><w c7="II">In</w><w c7="MC">1973</w><w c7=",">,</w><w c7="AT">the</w><w c7="JJ">synthetic</w><w c7="NN1">estrogen</w><w c7="NN1">blocker</w><w c7="NN1">tamoxifen</w><w c7="VBDZ">was</w><w c7="VVN">licensed</w><w c7="IF">for</w><w c7="NN1">use</w><w c7="II">in</w><w c7="AT">the</w><w c7="NN1">treatment</w><w c7="IO">of</w><w c7="JJ">hormone-positive</w><w c7="NN1">breast</w><w c7="NN1">cancer</w><w c7="CC">and</w><w c7="VVD">became</w><w c7="AT">the</w><w c7="NN1">mainstay</w><w c7="IO">of</w><w c7="JJ">endocrine</w><w c7="NN1">therapy</w><w c7="IF">for</w><w c7="AT">the</w><w c7="MD">next</w><w c7="MC">30</w><w c7="NNT2">years</w><w c7="[">[</w><w c7="MC">54</w><w c7="]">]</w><w c7=".">.</w><w c7="RT">Today</w><w c7=",">,</w><w c7="JJ">endocrine</w><w c7="NN1">therapy</w><w c7="VVZ">constitutes</w><w c7="AT1">a</w><w c7="JJ">major</w><w c7="NN1">treatment</w><w c7="NN1">modality</w><w c7="II">in</w><w c7="JJ">ER-positive</w><w c7="NN1">breast</w><w c7="NN1">cancer</w><w c7="CC">and</w><w c7="VM">can</w><w c7="VBI">be</w><w c7="VVN">used</w><w c7="RR">alone</w><w c7="CC">or</w><w c7="II31">in</w><w c7="II32">addition</w><w c7="II33">to</w><w c7="NN1">chemotherapy</w><w c7=",">,</w><w c7="DDQ">which</w><w c7="VHZ">has</w><w c7="DAR">more</w><w c7="JJ">associated</w><w c7="NN1">toxicity</w><w c7="[">[</w><w c7="MCMC">55‚Äì58</w><w c7="]">]</w><w c7=".">.</w><w c7="RR">Indeed</w><w c7=",">,</w><w c7="NN2">studies</w><w c7="VH0">have</w><w c7="VVN">shown</w><w c7="PPH1">it</w><w c7="TO">to</w><w c7="VVI">provide</w><w c7="DAR">more</w><w c7="NN1">benefit</w><w c7="II">in</w><w c7="AT">the</w><w c7="JJ">adjuvant</w><w c7="NN1">setting</w><w c7="II">in</w><w c7="JJ">postmenopausal</w><w c7="NN2">women</w><w c7="IW">with</w><w c7="JJ">ER-positive</w><w c7="NN1">breast</w><w c7="NN1">cancer</w><w c7="CSN">than</w><w c7="NN1">doxorubicin</w><w c7="CC">or</w><w c7="JJ">taxane-containing</w><w c7="NN1">chemotherapy</w><w c7="[">[</w><w c7="MC">59</w><w c7=",">,</w><w c7="MC">60</w><w c7="]">]</w><w c7=".">.</w><w c7="JJ">Endocrine</w><w c7="NN2">therapies</w><w c7="VV0">work</w><w c7="II">by</w><w c7="VVG">manipulating</w><w c7="JJ">endocrine</w><w c7="NN1">signalling</w><w c7="II">by</w><w c7="AT">the</w><w c7="JJ">exogenous</w><w c7="NN1">administration</w><w c7="IO">of</w><w c7="NN1">hormone</w><w c7="NN2">antagonists</w><w c7="VVN">designed</w><w c7="TO">to</w><w c7="VVI">inhibit</w><w c7="AT">the</w><w c7="NN1">biosynthesis</w><w c7="CC">and</w><w c7="/">/</w><w c7="CC">or</w><w c7="NN1">activity</w><w c7="IO">of</w><w c7="NN1">estrogen</w><w c7=".">.</w><w c7="JJ">Endocrine</w><w c7="NN2">therapies</w><w c7="VBR">are</w><w c7="VVN">considered</w><w c7="TO">to</w><w c7="VBI">be</w><w c7="JJ">cytostatic</w><w c7="II21">rather</w><w c7="II22">than</w><w c7="JJ">cytotoxic</w><w c7=",">,</w><w c7="VVG">leading</w><w c7="II">to</w><w c7="JJ">reduced</w><w c7="NN1">proliferation</w><w c7="CC">and</w><w c7="NN1">reduction</w><w c7="IO">of</w><w c7="NN1">growth</w><w c7="NN1">rate</w><w c7="[">[</w><w c7="MC">61</w><w c7="]">]</w><w c7=".">.</w><w c7="II">At</w><w c7="AT">the</w><w c7="JJT">simplest</w><w c7="JJ">molecular</w><w c7="NN1">level</w><w c7=",">,</w><w c7="PPHS2">they</w><w c7="VV0">achieve</w><w c7="DD1">this</w><w c7="II">through</w><w c7="AT">the</w><w c7="NN1">arrest</w><w c7="IO">of</w><w c7="NN1">cell</w><w c7="NN1">cycle</w><w c7="II">in</w><w c7="NP1">G1/S</w><w c7="NN1">phase</w><w c7="[">[</w><w c7="MC">62</w><w c7="]">]</w><w c7=".">.</w><w c7="RT">Today</w><w c7=",">,</w><w c7="DA2">several</w><w c7="NN2">types</w><w c7="IO">of</w><w c7="JJ">endocrine</w><w c7="NN2">therapies</w><w c7="VV0">exist</w><w c7="CC">and</w><w c7="VBR">are</w><w c7="VVN">used</w><w c7="RR">commonly</w><w c7="II">in</w><w c7="AT">the</w><w c7="NN1">treatment</w><w c7="IO">of</w><w c7="JJ">ER-positive</w><w c7="NN1">breast</w><w c7="NN1">cancer</w><w c7="II">in</w><w c7="JJ">postmenopausal</w><w c7="NN2">women</w><w c7=".">.</w></p>
    <p><w c7="MD">First</w><w c7="VVN">synthesised</w><w c7="II">in</w><w c7="AT">the</w><w c7="MC2">1960s</w><w c7=",">,</w><w c7="NN1">tamoxifen</w><w c7="VBZ">is</w><w c7="AT1">a</w><w c7="JJ">selective</w><w c7="NN1">estrogen</w><w c7="NN1">receptor</w><w c7="NN1">modulator</w><w c7="(">(</w><w c7="NP1">SERM</w><w c7=")">)</w><w c7="(">(</w><w c7="NP2">Figures</w><w c7="MC1">1</w><w c7="CC">and</w><w c7="MC">2</w><w c7=")">)</w><w c7=".">.</w></p>
    <p><object type="graphic" /></p>
    <p><w c7="NP1">Figure</w><w c7="MC">2</w><w c7=":">:</w><w c7="NN1">Timeline</w><w c7="IO">of</w><w c7="NN1">approval</w><w c7="IF">for</w><w c7="JJ">endocrine</w><w c7="NN1">therapy</w><w c7="NN2">agents</w><w c7=".">.</w></p>
    <p><w c7="PPH1">It</w><w c7="VVZ">functions</w><w c7="II">by</w><w c7="VVG">disrupting</w><w c7="AT">the</w><w c7="NN1">estrogen</w><w c7="NN1">signalling</w><w c7="NN1">pathway</w><w c7="II">by</w><w c7="JJ">competitive</w><w c7="JJ">intranuclear</w><w c7="NN1">binding</w><w c7="II">to</w><w c7="NP1">ER</w><w c7=",">,</w><w c7="VVG">causing</w><w c7="AT1">a</w><w c7="JJ">conformational</w><w c7="NN1">change</w><w c7="II">to</w><w c7="AT">the</w><w c7="RR">subsequently</w><w c7="JJ">formed</w><w c7="NP1">ER</w><w c7="NN1">dimer</w><w c7="VVG">involving</w><w c7="AT">the</w><w c7="NN1">shift</w><w c7="IO">of</w><w c7="NN1">helix</w><w c7="MC">12</w><w c7="II">into</w><w c7="AT1">an</w><w c7="JJ">adjacent</w><w c7="NN1">coactivator</w><w c7="NN1">site</w><w c7="(">(</w><w c7="NP1">AF2</w><w c7=")">)</w><w c7=",">,</w><w c7="RR">thus</w><w c7="VVG">blocking</w><w c7="AT">the</w><w c7="NN1">binding</w><w c7="IO">of</w><w c7="AT">the</w><w c7="NN1">coactivator</w><w c7=",">,</w><w c7="DDQ">which</w><w c7="RR">significantly</w><w c7="VVZ">reduces</w><w c7="AT">the</w><w c7="NN1">level</w><w c7="IO">of</w><w c7="JJ">estrogen-regulated</w><w c7="NN1">gene</w><w c7="NN1">transcription</w><w c7="[">[</w><w c7="MC">21</w><w c7=",">,</w><w c7="MC">63</w><w c7=",">,</w><w c7="MC">64</w><w c7="]">]</w><w c7=".">.</w><w c7="RR">However</w><w c7=",">,</w><w c7="DD1">this</w><w c7="NN1">complex</w><w c7="VHZ">has</w><w c7="VBN">been</w><w c7="VVN">shown</w><w c7="TO">to</w><w c7="VVI">exhibit</w><w c7="JJ">partial</w><w c7="JJ">estrogen-agonist</w><w c7="NN2">properties</w><w c7="II21">due</w><w c7="II22">to</w><w c7="AT">the</w><w c7="JJ">remaining</w><w c7="NN1">activity</w><w c7="IO">of</w><w c7="NP1">AF1</w><w c7="[">[</w><w c7="MC1">1</w><w c7=",">,</w><w c7="MC">21</w><w c7="]">]</w><w c7=".">.</w><w c7="AT1">A</w><w c7="JJR">newer</w><w c7="RR">yet</w><w c7="JJ">similar</w><w c7="NN1">class</w><w c7="IO">of</w><w c7="JJ">endocrine</w><w c7="NN2">therapies</w><w c7="RR">also</w><w c7="VV0">exist</w><w c7="DDQ">which</w><w c7="VBR">are</w><w c7="VVN">known</w><w c7="II">as</w><w c7="JJ">selective</w><w c7="NN1">estrogen</w><w c7="NN1">receptor</w><w c7="NN2">downregulators</w><w c7="(">(</w><w c7="NP2">SERDs</w><w c7=")">)</w><w c7="CC">and</w><w c7="DD2">these</w><w c7="VV0">include</w><w c7="NN1">fulvestrant</w><w c7=",">,</w><w c7="DDQ">which</w><w c7="VBDZ">was</w><w c7="MD">first</w><w c7="VVN">approved</w><w c7="IF">for</w><w c7="NN1">use</w><w c7="II">in</w><w c7="MC">2002</w><w c7=".">.</w><w c7="NN1">Fulvestrant</w><w c7="VVZ">functions</w><w c7="TO">to</w><w c7="VVI">downregulate</w><w c7="NP1">ER</w><w c7="II">by</w><w c7="JJ">competitive</w><w c7="NN1">binding</w><w c7="II">to</w><w c7="NP1">ER</w><w c7="NN2">dimers</w><w c7="CC">and</w><w c7="II">by</w><w c7="VVG">causing</w><w c7="NN1">immobilisation</w><w c7="IO">of</w><w c7="NP1">ER</w><w c7="II">in</w><w c7="AT">the</w><w c7="JJ">nuclear</w><w c7="NN1">matrix</w><w c7="DDQ">which</w><w c7="VBZ">is</w><w c7="VVN">accompanied</w><w c7="II">by</w><w c7="NN1">degradation</w><w c7="II">via</w><w c7="AT">the</w><w c7="NN1">ubiquitin-proteasome</w><w c7="NN1">pathway</w><w c7="[">[</w><w c7="MC">65</w><w c7="]">]</w><w c7="(">(</w><w c7="NP2">Figures</w><w c7="MC1">1</w><w c7="CC">and</w><w c7="MC">2</w><w c7=")">)</w><w c7=".">.</w><w c7="PPH1">It</w><w c7="VHZ">has</w><w c7="VBN">been</w><w c7="VVN">shown</w><w c7="TO">to</w><w c7="VBI">be</w><w c7="RGR">more</w><w c7="JJ">potent</w><w c7="CSN">than</w><w c7="NN1">tamoxifen</w><italics><w c7="RR21">in</w><w c7="RR22">vitro</w></italics><w c7="CC">and</w><w c7="VDZ">does</w><w c7="XX">not</w><w c7="VVI">exhibit</w><w c7="AT">the</w><w c7="JJ">partial</w><w c7="JJ">estrogen-agonist</w><w c7="NN2">properties</w><w c7="VVN">associated</w><w c7="IW">with</w><w c7="NN1">tamoxifen</w><w c7="II">in</w><w c7="JJ">murine</w><w c7="NN2">models</w><w c7=".">.</w><w c7="DD1">This</w><w c7="VBZ">is</w><w c7="II21">due</w><w c7="II22">to</w><w c7="AT">the</w><w c7="NN1">fact</w><w c7="CST">that</w><w c7="RR">both</w><w c7="NP1">AF1</w><w c7="CC">and</w><w c7="NP1">AF2</w><w c7="NN2">activities</w><w c7="VBR">are</w><w c7="VVN">suppressed</w><w c7=",">,</w><w c7="VVG">blocking</w><w c7="NN1">cofactor</w><w c7="NN1">recruitment</w><w c7="II">at</w><w c7="AT">the</w><w c7="NP1">ERE</w><w c7="NN1">site</w><w c7="IO">of</w><w c7="NN1">estrogen</w><w c7="JJ">responsive</w><w c7="NN2">genes</w><w c7="[">[</w><w c7="MC">21</w><w c7=",">,</w><w c7="MC">66</w><w c7=",">,</w><w c7="MC">67</w><w c7="]">]</w><w c7=".">.</w></p>
    <p><w c7="DD1">Another</w><w c7="JJ">major</w><w c7="NN1">group</w><w c7="IO">of</w><w c7="JJ">endocrine</w><w c7="NN2">therapies</w><w c7="II">in</w><w c7="JJ">routine</w><w c7="JJ">clinical</w><w c7="NN1">use</w><w c7="VBR">are</w><w c7="JJ">third-generation</w><w c7="NN1">aromatase</w><w c7="NN2">inhibitors</w><w c7="(">(</w><w c7="NP2">AIs</w><w c7=")">)</w><w c7=",">,</w><w c7="DDQ">which</w><w c7="VV0">comprise</w><w c7="MC">two</w><w c7="NN1">drug</w><w c7="NN2">types</w><w c7=".">.</w><w c7="RR">Firstly</w><w c7=",">,</w><w c7="AT">the</w><w c7="JJ">irreversible</w><w c7="JJ">steroidal</w><w c7="NN2">inhibitors</w><w c7="(">(</w><w c7="NN1">type</w><w c7="MC1">1</w><w c7=")">)</w><w c7=",">,</w><w c7="II">including</w><w c7="NN1">exemestane</w><w c7="DDQ">which</w><w c7="VBR">are</w><w c7="NN1">androstenedione</w><w c7="NN2">analogues</w><w c7="CC">and</w><w c7="RR">secondly</w><w c7=",">,</w><w c7="AT">the</w><w c7="JJ">non-steroidal</w><w c7="NN2">inhibitors</w><w c7="(">(</w><w c7="NN1">type</w><w c7="MC">2</w><w c7=")">)</w><w c7=",">,</w><w c7="DDQ">which</w><w c7="VV0">include</w><w c7="NN1">letrozole</w><w c7="CC">and</w><w c7="NN1">anastrozole</w><w c7="[">[</w><w c7="MC1">1</w><w c7=",">,</w><w c7="MCMC">68‚Äì73</w><w c7="]">]</w><w c7="(">(</w><w c7="NP2">Figures</w><w c7="MC1">1</w><w c7="CC">and</w><w c7="MC">2</w><w c7=")">)</w><w c7=".">.</w><w c7="NP2">AIs</w><w c7="VV0">seek</w><w c7="TO">to</w><w c7="VVI">disrupt</w><w c7="NN1">estrogen</w><w c7="NN1">signalling</w><w c7="II">by</w><w c7="RR">either</w><w c7=":">:</w><w c7="JJ">irreversible</w><w c7="CC">and</w><w c7="JJ">inactivating</w><w c7="NN1">binding</w><w c7="(">(</w><w c7="NN1">type</w><w c7="MC1">1</w><w c7=")">)</w><w c7=",">,</w><w c7="CC">or</w><w c7="JJ">reversible</w><w c7="CC">and</w><w c7="JJ">competitive</w><w c7="NN1">binding</w><w c7="(">(</w><w c7="NN1">type</w><w c7="MC">2</w><w c7=")">)</w><w c7="II">to</w><w c7="AT">the</w><w c7="NN1">aromatase</w><w c7="NN1">enzyme</w><w c7=";">;</w><w c7="RR">thus</w><w c7="RR">significantly</w><w c7="VVG">reducing</w><w c7="JJ">local</w><w c7="NN1">estrogen</w><w c7="NN1">biosynthesis</w><w c7="CC">and</w><w c7="RR">hence</w><w c7="JJ">intratumoural</w><w c7="NN2">levels</w><w c7="IO">of</w><w c7="NN1">estrogen</w><w c7="[">[</w><w c7="MC1">1</w><w c7=",">,</w><w c7="MCMC">74‚Äì76</w><w c7="]">]</w><w c7=".">.</w><w c7="RR">Indeed</w><w c7=",">,</w><w c7="II">in</w><w c7="AT">the</w><w c7="JJ">adjuvant</w><w c7="NN1">setting</w><w c7=",">,</w><w c7="NN1">letrozole</w><w c7=",">,</w><w c7="NN1">anastrozole</w><w c7="CC">and</w><w c7="NN1">exemestane</w><w c7="VH0">have</w><w c7="VBN">been</w><w c7="VVN">shown</w><w c7="TO">to</w><w c7="VBI">be</w><w c7="RGR">more</w><w c7="JJ">effective</w><w c7="CSN">than</w><w c7="NN1">tamoxifen</w><w c7="IW">with</w><w c7="AT1">a</w><w c7="JJ">significant</w><w c7="NN1">reduction</w><w c7="II">in</w><w c7="AT">the</w><w c7="NN1">rate</w><w c7="IO">of</w><w c7="NN1">relapse</w><w c7="[">[</w><w c7="MC">73</w><w c7=",">,</w><w c7="MCMC">77‚Äì79</w><w c7="]">]</w><w c7=".">.</w><w c7="JJ">Endocrine</w><w c7="NN2">therapies</w><w c7="VM">can</w><w c7="RR">also</w><w c7="VBI">be</w><w c7="VVN">used</w><w c7="II">in</w><w c7="AT">the</w><w c7="NN1">treatment</w><w c7="IO">of</w><w c7="JJ">ER-positive</w><w c7="NN1">breast</w><w c7="NN1">cancer</w><w c7="II">in</w><w c7="JJ">premenopausal</w><w c7="NN2">women</w><w c7="CS">where</w><w c7="APPGE">their</w><w c7="NN1">use</w><w c7="VBZ">is</w><w c7="RR">usually</w><w c7="VVN">combined</w><w c7="IW">with</w><w c7="NN2">drugs</w><w c7="II21">such</w><w c7="II22">as</w><w c7="NN1">goserelin</w><w c7="(">(</w><w c7="NN1">zoladex</w><w c7=")">)</w><w c7="TO">to</w><w c7="VVI">suppress</w><w c7="JJ">ovarian</w><w c7="NN1">estrogen</w><w c7="NN1">production</w><w c7="[">[</w><w c7="MC">80</w><w c7="]">]</w><w c7=".">.</w></p>
    <p><w c7="II">In</w><w c7="JJ">postmenopausal</w><w c7="NN2">women</w><w c7=",">,</w><w c7="JJ">adjuvant</w><w c7="NN1">treatment</w><w c7="VVZ">represents</w><w c7="AT">the</w><w c7="JJ">major</w><w c7="JJ">clinical</w><w c7="NN1">setting</w><w c7="IF">for</w><w c7="JJ">endocrine</w><w c7="NN1">therapy</w><w c7=",">,</w><w c7="CS">where</w><w c7="JJ">long-term</w><w c7="JJ">adjuvant</w><w c7="JJ">systemic</w><w c7="NN1">treatment</w><w c7="VBZ">is</w><w c7="VVN">targeted</w><w c7="II">against</w><w c7="JJ">micro-metastatic</w><w c7="NN1">disease</w><w c7="[">[</w><w c7="MC">2</w><w c7="]">]</w><w c7=".">.</w><w c7="RR">Indeed</w><w c7=",">,</w><w c7="DA2">several</w><w c7="NN2">studies</w><w c7="VH0">have</w><w c7="VVN">reported</w><w c7="JJ">overwhelming</w><w c7="NN1">evidence</w><w c7="IO">of</w><w c7="AT1">a</w><w c7="JJ">high</w><w c7="NN1">correlation</w><w c7="II">between</w><w c7="AT">the</w><w c7="JJ">adjuvant</w><w c7="NN1">use</w><w c7="IO">of</w><w c7="JJ">endocrine</w><w c7="NN1">therapy</w><w c7="CC">and</w><w c7="NN1">reduction</w><w c7="II">in</w><w c7="AT">the</w><w c7="NN1">risk</w><w c7="IO">of</w><w c7="NN1">recurrence</w><w c7="[">[</w><w c7="MC">81</w><w c7="]">]</w><w c7=".">.</w><w c7="JJ">Endocrine</w><w c7="NN1">therapy</w><w c7="VM">can</w><w c7="RR">also</w><w c7="VHI">have</w><w c7="AT1">an</w><w c7="JJ">important</w><w c7="NN1">role</w><w c7="II">in</w><w c7="AT">the</w><w c7="JJ">neoadjuvant</w><w c7="NN1">setting</w><w c7="CS">where</w><w c7="JJ">systemic</w><w c7="NN1">treatment</w><w c7="VM">may</w><w c7="VBI">be</w><w c7="VVN">indicated</w><w c7="IF">for</w><w c7="MC">3</w><w c7="II">to</w><w c7="MC">4</w><w c7="NNT2">months</w><w c7="II21">prior</w><w c7="II22">to</w><w c7="NN1">surgery</w><w c7="II">in</w><w c7="JJ">postmenopausal</w><w c7="NN2">women</w><w c7="IW">with</w><w c7="JJ">large</w><w c7="CC">and</w><w c7="/">/</w><w c7="CC">or</w><w c7="RR">technically</w><w c7="JJ">inoperable</w><w c7="NN2">tumours</w><w c7=".">.</w><w c7="DD1">This</w><w c7="NN1">treatment</w><w c7="VBZ">is</w><w c7="VVN">intended</w><w c7="TO">to</w><w c7="VVI">shrink</w><w c7="AT">the</w><w c7="NN1">tumour</w><w c7="CS21">so</w><w c7="CS22">that</w><w c7=",">,</w><w c7="II">in</w><w c7="RR">locally</w><w c7="JJ">advanced</w><w c7="NN1">disease</w><w c7="NN1">surgery</w><w c7="VVZ">becomes</w><w c7="JJ">possible</w><w c7="CC">and</w><w c7="II">in</w><w c7="JJ">large</w><w c7="JJ">operable</w><w c7="NN1">breast</w><w c7="NN2">cancers</w><w c7=",">,</w><w c7="NN1">breast</w><w c7="JJ">conserving</w><w c7="NN1">surgery</w><w c7="(">(</w><w c7="NP1">BCS</w><w c7=")">)</w><w c7="VM">can</w><w c7="VBI">be</w><w c7="VVN">performed</w><w c7="[">[</w><w c7="MC">2</w><w c7=",">,</w><w c7="MC">56</w><w c7="]">]</w><w c7=".">.</w><w c7="AT">The</w><w c7="JJ">Immediate</w><w c7="JJ">Preoperative</w><w c7="NP1">Anastrozole</w><w c7="CC">or</w><w c7="VVN">Combined</w><w c7="IW">with</w><w c7="NP1">Tamoxifen</w><w c7="(">(</w><w c7="NP1">IMPACT</w><w c7=")">)</w><w c7="NN1">study</w><w c7="VBDZ">was</w><w c7="AT1">a</w><w c7="NN1">phase</w><w c7="MC">3</w><w c7="JJ">clinical</w><w c7="NN1">trial</w><w c7="DDQ">which</w><w c7="VVD">showed</w><w c7="CST">that</w><w c7="MC">46</w><w c7="NNU">%</w><w c7="IO">of</w><w c7="MC">124</w><w c7="JJ">ER-positive</w><w c7="JJ">postmenopausal</w><w c7="NN2">women</w><w c7="RR">initially</w><w c7="VVN">recommended</w><w c7="IF">for</w><w c7="NN1">mastectomy</w><w c7="VVD">became</w><w c7="JJ">eligible</w><w c7="IF">for</w><w c7="NP1">BCS</w><w c7="VVG">following</w><w c7="MC">3</w><w c7="NNT2">months</w><w c7="IO">of</w><w c7="JJ">neoadjuvant</w><w c7="NN1">anastrozole</w><w c7="[">[</w><w c7="MC">82</w><w c7="]">]</w><w c7=".">.</w><w c7="JJ">Similar</w><w c7="NN2">results</w><w c7="VBDR">were</w><w c7="VVN">found</w><w c7="II">in</w><w c7="AT1">a</w><w c7="NN1">study</w><w c7="IO">of</w><w c7="NN1">exemestane</w><w c7="II">in</w><w c7="DDQ">which</w><w c7="MC">85</w><w c7="NNU">%</w><w c7="IO">of</w><w c7="MC">40</w><w c7="NN2">patients</w><w c7="VVN">deemed</w><w c7="JJ">unfit</w><w c7="IF">for</w><w c7="NP1">BCS</w><w c7="II">at</w><w c7="NN1">diagnosis</w><w c7="VVD">became</w><w c7="JJ">eligible</w><w c7="VVG">following</w><w c7="MC">6</w><w c7="NNT2">months</w><w c7="IO">of</w><w c7="JJ">neoadjuvant</w><w c7="NN1">therapy</w><w c7="[">[</w><w c7="MC">83</w><w c7="]">]</w><w c7=".">.</w><w c7="RR">Indeed</w><w c7="II">by</w><w c7="VVG">measuring</w><w c7="NN1">proliferation</w><w c7="NN2">levels</w><w c7="IO">of</w><w c7="JJ">malignant</w><w c7="NN2">cells</w><w c7="VVG">using</w><w c7="AT">the</w><w c7="NN1">expression</w><w c7="IO">of</w><w c7="JJ">nuclear</w><w c7="NN1">antigen</w><w c7="NP1">Ki67</w><w c7=",">,</w><w c7="NN2">studies</w><w c7="VH0">have</w><w c7="VVN">shown</w><w c7="AT1">a</w><w c7="NN1">reduction</w><w c7="II">in</w><w c7="NN1">proliferation</w><w c7="II">in</w><w c7="RR">approximately</w><w c7="MC">90</w><w c7="NNU">%</w><w c7="IO">of</w><w c7="JJ">ER-positive</w><w c7="JJ">primary</w><w c7="NN1">breast</w><w c7="NN2">tumours</w><w c7="VVN">treated</w><w c7="IW">with</w><w c7="CC">and</w><w c7="JJ">responsive</w><w c7="II">to</w><w c7="NP2">AIs</w><w c7=",">,</w><w c7="VVG">confirming</w><w c7="CST">that</w><w c7="DD2">these</w><w c7="NN2">tumours</w><w c7="VV0">derive</w><w c7="JJ">significant</w><w c7="JJ">proliferative</w><w c7="NN1">stimulus</w><w c7="II">from</w><w c7="NN1">estrogen</w><w c7="CC">and</w><w c7="CST">that</w><w c7="DD1">this</w><w c7="VM">can</w><w c7="VBI">be</w><w c7="RR">potently</w><w c7="VVN">supressed</w><w c7="II">by</w><w c7="JJ">endocrine</w><w c7="NN1">therapy</w><w c7="[">[</w><w c7="MC">84</w><w c7=",">,</w><w c7="MC">85</w><w c7="]">]</w><w c7=".">.</w><w c7="JJ">Endocrine</w><w c7="NN1">therapy</w><w c7="VM">can</w><w c7="RR">also</w><w c7="VBI">be</w><w c7="VVN">used</w><w c7="II">in</w><w c7="AT">the</w><w c7="NN1">treatment</w><w c7="IO">of</w><w c7="JJ">advanced</w><w c7="CC">or</w><w c7="JJ">metastatic</w><w c7="NN1">disease</w><w c7="TO">to</w><w c7="VVI">prolong</w><w c7="NN1">survival</w><w c7=",">,</w><w c7="RR">either</w><w c7="II">as</w><w c7="AT1">a</w><w c7="NN1">monotherapy</w><w c7="CC">or</w><w c7="II">as</w><w c7="NN1">part</w><w c7="IO">of</w><w c7="AT1">a</w><w c7="JJ">sequenced</w><w c7="NN1">treatment</w><w c7="NN1">regimen</w><w c7="IW">with</w><w c7="NN1">chemotherapy</w><w c7=",">,</w><w c7="JJ">palliative</w><w c7="NN1">surgery</w><w c7="CC">or</w><w c7="NN1">radiotherapy</w><w c7="[">[</w><w c7="MC">86</w><w c7="]">]</w><w c7=".">.</w></p>
  </text>
</annotated>